STABLE LIQUID PHARMACEUTICAL FORMULATION OF ANTIBODIES THAT ARE PRONE TO ISOMERIZATION

摘要

This invention is directed to a stable liquid pharmaceutical formulation comprising an antibody that is prone to isomerization, and 10-120 mM MgCl2. The antibody comprises at least two aspartic acid residues or one aspartic acid and one glutamic acid residue in its primary sequence. The aspartic acid tends to form a succinimide intermediate and isoAsp, thus causes the antibody to lose stability. The addition of MgCl2 in the antibody formulation slows down the isomerization and stabilizes the antibody. This invention is exemplified by a stabilized liquid formulation of HuMv833, a monoclonal antibody against vascular endothelial growth factor (VEGF).